Study shows local standards of care affect the benefits of switching to new treatement alternatives

Aug 29, 2010

An analysis of a trial into how a new drug dabigatran was effective in preventing stroke in patients with atrial fibrillation has shown that local standards of care affect the benefits of switching to new treatments. This analysis of the RELY trial is reported in an Article Online First and in an upcoming Lancet, and is being presented at this week's European Society of Cardiology meeting in Stockholm, Sweden. The Article is by Professor Lars Wallentin, Uppsala University, Sweden, and colleagues.

The RELY study compared standard warfarin treatment with 110mg and 150mg twice daily doses of dabigatran. For warfarin treatment to be both safe and effective, blood tests are used to monitor its effects, which need to be kept within a very narrow window. This requires close monitoring and dose changes. As shown in the study there are large variations in standards of warfarin care between different centres and different countries. The standards of care can be estimated by averaging the time in the therapeutic range (TTR) for all warfarin treated patients in a centre (cTTR).This new analysis looked at whether or not the benefits shown by dabigatran in RELY were consistent even in centres that had poor INR quality control as estimated by cTTR.

The researchers showed there were fewer ischaemic strokes but not fewer occurrences of intracranial bleeding with increasing cTTR in the warfarin group. The value of cTTR had no effect influence on the the effect of dabigatran versus warfarin for preventing stroke. However, concerning cardiovascular mortality, bleeding and all cardiovascular events there risks were higher at centres with lower cTTR. Therefore concerning these events advantages of dabigatran versus warfarin were considerably larger at sites with poor standards of care.

The authors say: "Thus, these findings support the superiority of 150mg dabigatran twice daily and the non-inferiority of 110mg dabigatran twice daily versus warfarin for protection against in atrial fibrillation irrespective of the quality of INR control that a centre can achieve."

But they add: "For secondary outcomes, such as non-haemorrhagic events and mortaility, advantages of dabigatran were reported for sites with poorer INR control, whereas results were comparable in sites with better INR control. Overall, these results show that local standards of care affect the benefits of switching to new treatment alternatives."

In a linked Comment, Dr Deirdre A Lane and Professor Gregory Y H Lip, University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK, says the findings mean oral anticoagulants would probably be advocated for an even greater proportion of patients with atrial , in view of the future availability of the new oral anticoagulants, such as dabigatran, that overcome the disadvantages of warfarin.

They conclude: "Until the new oral anticoagulants become widely available (a positive advance), we should advocate tight INR control at conventional levels, for which there is a wealth of evidence for benefit, and promote strategies to improve the management of therapy with vitamin K antagonists [such as ]."

Explore further: Secret of tetanus toxicity offers new way to treat motor neuron disease

More information: www.thelancet.com/journals/lan… (10)61194-4/abstract

add to favorites email to friend print save as pdf

Related Stories

New blood-thinning drug safer than rat poison

Sep 29, 2009

In an article reviewed by F1000 Medicine Faculty Members Robert Ruff, Brian Olshansky and Luis Ruilope, the blood-thinner dabigatran is shown to protect against stroke, blood clotting and major bleeding as effectively as ...

Study shows experimental drug cuts stroke risk

Aug 30, 2009

(AP) -- An experimental drug reduces the stroke risk in patients with irregular heartbeats by more than three times, compared with the popular drug warfarin - but possibly at a cost, according to new research released Sunday.

Blood-Thinning Drug Linked to Increased Bleeding in Brain

Sep 29, 2008

(PhysOrg.com) -- Patients who take the commonly used blood-thinning drug warfarin face larger amounts of bleeding in the brain and increased risk of mortality if they suffer a hemorrhagic stroke, new research from the University ...

Genetics determine optimal drug dose of common anticoagulant

Aug 21, 2007

Genetic testing can be used to help personalize the therapeutic dosage of warfarin, a commonly-used anticoagulant, according to research published in the September 1, 2007, issue of Blood, the journal of the American Societ ...

Recommended for you

Stroke damage mechanism identified

22 hours ago

Researchers have discovered a mechanism linked to the brain damage often suffered by stroke victims—and are now searching for drugs to block it.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.